-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hangzhou, October 12, 2021/PRNewswire/ - Citing innovative treatment strategies, the world’s first innovative treatment plan-Liwen RF™ radiofrequency ablation system developed by Nuocheng Medical and Professor Liu Liwen of Xijing Hospital to bring patients with hypertrophic cardiomyopathy Come to the gospel
Current status of treatment of hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (hereinafter referred to as "hypertrophic heart disease") is the most common inherited cardiovascular disease.
At present, the treatment of obese heart disease mainly includes drug therapy, alcohol ablation of the ventricular septum, and surgical (rotary septal resection)
Combination of medicine and industry, Nuocheng Medical's leading layout
Adhering to the concept of technological innovation to solve international clinical pain points, Nuocheng Medical and Professor Liu Liwen from Xijing Hospital brought together a team of clinical experts and engineers to successfully develop the world's first product that applies radio frequency to treat hypertrophic cardiomyopathy-Liwen RF™ radio frequency ablation system
The clinical evidence is encouraging
The Liwen RF™ radio frequency ablation system has successfully completed the exploratory clinical research of the new technology, and has now officially entered the stage of registered clinical trials (evaluating the prospective, prospective, Multi-center, single-group target value method clinical research), the research is led by Academician Ge Junbo and Academician Zhang Yun, with Professor Liu Liwen as the main investigator, International TCT Chair Professor Martin Leon, CSI Chair Professor Horst Sievert, and Professor Chaim Lotan as the research Consultant, fourteen tertiary hospitals across the country participated in the research and meticulously built the world's top clinical investigator team
The study has so far successfully enrolled 28 patients.
Researcher's Message
Professor Liu Liwen from Xijing Hospital said: Liwen RF™ radio frequency ablation system, the design of adjustable ablation needle can adjust the size of the ablation focus in real time according to the thickness of the myocardium, and can selectively ablate the base, middle and near apex of the ventricular septum, which is effective It makes up for the shortcomings of the previous surgical treatment of obese heart disease, and shows obvious advantages in safety and effectiveness
Source: Nuocheng Medical